, Tracking Stock Market Picks
Enter Symbol:
Mannkind Corporation (MNKD) [hlAlert]

up 148.59 %

Mannkind Corporation (MNKD) downgraded to Underperform by Oppenheimer

Posted on: Friday,  Sep 25, 2009  8:25 AM ET by Oppenheimer

Oppenheimer rated Underperform Mannkind Corporation (NASDAQ: MNKD) on 09/25/2009. Previously Oppenheimer rated Perform
Mannkind Corporation (NASDAQ: MNKD) on 12/18/2008., when the stock price was $3.60. Since then, Mannkind Corporation has gained 170.00% as of 09/25/2009's recent price of $9.72.

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/25/2009 8:25 AM Sell
as of 12/31/2009
1 Week up  34.91 %
1 Month up  20.66 %
3 Months up  41.52 %
1 YTD up  40.74 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/18/2008 8:25 AM None
8/6/2007 9:25 AM Hold

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy